Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis: A protocol for systematic review and meta-analysis.
Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis: A protocol for systematic review and meta-analysis.
复制标题
甲氨蝶呤与来氟米特治疗类风湿性关节炎的临床疗效及安全性比较
DOI：
10.1097/md.0000000000028285
复制
发表时间：
2021-12-23
期刊：
影响因子：
1.6
通讯作者：
Cao J
中科院分区：
文献类型：
--
作者：
Qi W;Xia Y;Li X;Cao J
摘要背景：甲氨蝶呤和来氟米特是类风湿关节炎（RA）的经典治疗方法，但哪一种是RA患者的最佳选择仍是临床上的一个重要问题，本文采用Meta分析方法系统评价和比较两种药物的疗效和安全性。研究方法：检索PubMed、Cochrance Library、Embase、SinoMed、中国知网、中国科技期刊数据库、万方数据库。检索时间为成立至2021年9月7日。根据科克伦偏倚风险工具进行文献筛选、数据提取和质量评估。采用RevMan 5.3软件和Stata 12.0软件对纳入研究进行Meta分析。结果如下：采用美国风湿病学会（ACR）20/50/70、DAS 28、总有效率、不良反应发生率、晨僵、关节肿胀数、关节压痛数、血沉、C反应蛋白、类风湿因子等指标评价来氟米特和甲氨蝶呤的临床疗效和安全性。结论：本Meta分析的结果将为类风湿关节炎的临床疗效和安全性提供可靠依据。仍需更多高质量的随机对照试验为RA的治疗提供更可靠的证据。PROSPERO编号：CRD 42021270980
Abstract Background: Methotrexate and leflunomide are classic treatments for rheumatoid arthritis (RA), however, which is the best choice for patients of RA is still an important question clinically, and this meta-analysis is used to systematically evaluate and compare their efficacy and safety. Methods: We searched PubMed, Cochrance Library, Embase, SinoMed, China National Knowledge Infrastructure, China Science and Technology Journal Database, WanFang Data databases. The retrieval time was from the establishment to September 7, 2021. Literature screening, data extraction, and quality assessment were performed according to the Cochrane risk of bias tool. Meta-analysis of the included studies was performed using RevMan 5.3 software and Stata 12.0 software. Results: The clinical efficacy and safety of leflunomide and methotrexate are evaluated by American College of Rheumatology (ACR)20/50/70, DAS28, total effective rate, adverse reaction rate, morning stiffness, swollen joint count, tender joint count, erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor. Conclusion: The results of this meta-analysis will provide reliable evidence clinical efficacy and safety for RA. More high-quality randomized controlled trials are still needed to provide more reliable evidence for the treatment of RA. PROSPERO number: CRD42021270980